21^st World Drug Delivery Summit

Drug Delivery Summit

Drug Delivery 2027

April 08-09, 2027 | Vienna, Austria

Welcome to the 21^st World Drug Delivery Summit We are delighted to invite you to this premier international gathering of professionals and experts in the field of drug delivery. This conference promises to be a platform for sharing knowledge, fostering innovation, and driving advancements in drug delivery technologies, all set against the backdrop of the historic and beautiful city of Vienna, Austria.

About Conference

The Drug Delivery 2027 Summit is a distinguished event that brings together leading researchers, scientists, pharmaceutical professionals, clinicians, and industry experts from around the world. This two-day conference offers a unique opportunity to explore and discuss the latest developments, breakthroughs, and challenges in the realm of drug delivery.

Conference Highlights:

1. Cutting-Edge Research: Engage with renowned experts as they present groundbreaking research findings in drug delivery systems, nanotechnology, biomaterials, and more.
2. Interdisciplinary Collaboration: Foster collaboration between various disciplines, including pharmaceutical sciences, engineering, medicine, and chemistry, to accelerate drug delivery innovations.
3. Keynote Speakers: Gain insights from keynote speakers who are pioneers in the field, offering their perspectives on the future of drug delivery.
4. Interactive Workshops: Participate in interactive workshops and hands-on sessions to enhance your practical skills and knowledge.
5. Exhibition Area: Explore a vibrant exhibition area featuring the latest advancements in drug delivery technologies, products, and services.
6. Networking Opportunities: Connect with peers, researchers, and industry leaders, paving the way for potential collaborations and partnerships.

Why Attend:

• Stay Informed: Stay updated on the latest trends, challenges, and opportunities in drug delivery research and development.
• Connect: Network with professionals from academia, industry, and healthcare, fostering connections that can lead to future collaborations.
• Learn: Benefit from the insights of leading experts and gain valuable knowledge that can be applied to your work.
• Inspiration: Be inspired by cutting-edge research and innovative solutions that have the potential to improve patient outcomes.

Who Should Attend:

• Pharmaceutical Scientists
• Pharmacists
• Researchers and Academics
• Biomedical Engineers
• Clinical Pharmacologists
• Regulatory Affairs Specialists
• Materials Scientists
• Medical Practitioners
• Quality Assurance Professionals
• Marketing and Sales Specialists

Join us in Vienna, Austria on April 08-09, 2027, to be a part of this exceptional gathering. Be prepared to immerse yourself in the world of drug delivery, exchange ideas, and contribute to the future of healthcare. Together, let's shape the future of drug delivery and make a positive impact on patient care.

We look forward to welcoming you to the 21^st World Drug Delivery Summit in the historic and enchanting city of Vienna.

Sessions & Tracks

Track 1: Advanced Drug Delivery Systems & Technologies

This track focuses on emerging technologies designed to improve the delivery, efficacy, safety, and therapeutic performance of pharmaceutical agents. Sessions will explore innovative delivery platforms including nanoparticles, liposomes, micelles, dendrimers, polymeric systems, nanogels, hydrogels, implantable devices, and stimuli-responsive carriers. Particular attention will be given to technologies capable of controlling drug release and directing therapeutic compounds toward specific tissues or cellular targets. Researchers will discuss recent advances in formulation engineering, carrier design, drug-loading strategies, stability enhancement, and controlled-release mechanisms. The track will also address challenges associated with translating advanced delivery technologies from laboratory research into clinically viable products. Emerging approaches integrating artificial intelligence, computational modeling, and high-throughput screening will be considered as tools for accelerating formulation development. Discussions will encourage collaboration between pharmaceutical scientists, engineers, clinicians, biotechnology companies, and regulatory experts to advance next-generation drug delivery technologies from discovery through commercialization.

Track 2: Nanomedicine & Nanoparticle-Based Drug Delivery

Nanotechnology is transforming drug delivery by enabling precise control over therapeutic transport, release, and biodistribution. This track examines the latest developments in nanoparticle-based systems, including lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, nanocrystals, nanocomplexes, and hybrid nanocarriers. Sessions will explore strategies for improving drug solubility, stability, bioavailability, cellular uptake, and therapeutic selectivity. Researchers will discuss surface engineering, ligand-mediated targeting, stealth technologies, intracellular delivery, and stimuli-responsive nanoparticles. Particular emphasis will be placed on the translation of nanomedicines into clinical applications and the challenges associated with manufacturing, characterization, scalability, toxicity, and regulatory approval. Applications across oncology, infectious diseases, neurological disorders, cardiovascular conditions, and genetic medicine will be highlighted. The track will also examine emerging opportunities in personalized nanomedicine and precision therapeutics. Scientific discussions will provide an interdisciplinary platform for exchanging knowledge on how nanoscale engineering can improve therapeutic outcomes while minimizing systemic toxicity and unwanted drug exposure.

Track 3: Targeted & Precision Drug Delivery

Targeted drug delivery aims to transport therapeutic agents selectively to diseased tissues while minimizing exposure to healthy organs. This track explores innovative strategies for achieving spatial and temporal control over drug distribution. Sessions will cover passive and active targeting, receptor-mediated delivery, antibody-drug conjugates, ligand-functionalized carriers, cell-specific targeting, and tissue-selective delivery systems. Speakers will examine how molecular biomarkers, disease characteristics, and patient-specific biological factors can guide the development of precision delivery platforms. Particular attention will be given to targeted cancer therapy, inflammatory diseases, neurological disorders, and rare diseases. The track will also address challenges such as biological barriers, heterogeneous receptor expression, immune recognition, and limited penetration into solid tissues. Advances in imaging-guided delivery and theranostic platforms will be discussed as approaches for simultaneously monitoring and treating disease. By integrating pharmaceutical sciences, molecular biology, bioengineering, and clinical research, this track will highlight opportunities to make drug delivery more precise, effective, and patient-centered.

Track 4: Lipid Nanoparticles, Liposomes & Lipid-Based Delivery

Lipid-based delivery systems have become important platforms for transporting small molecules, proteins, peptides, nucleic acids, and other advanced therapeutics. This track focuses on the design, formulation, characterization, and clinical translation of liposomes, lipid nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, and related systems. Sessions will explore lipid composition, particle size, surface properties, encapsulation efficiency, stability, release behavior, and biological interactions. Particular attention will be given to lipid nanoparticles for RNA delivery and their expanding applications in vaccines and genetic medicines. Researchers will discuss strategies for improving tissue targeting, reducing toxicity, overcoming biological barriers, and enhancing intracellular delivery. Manufacturing challenges, scale-up processes, quality control, storage stability, and regulatory considerations will also be addressed. The track will provide opportunities to examine how advances in lipid chemistry, formulation science, and nanotechnology are creating more effective delivery systems for complex therapeutic molecules and enabling new generations of vaccines, gene therapies, and precision medicines.

Track 5: Oral, Transdermal & Mucosal Drug Delivery

Alternative routes of administration can improve patient convenience, treatment adherence, and therapeutic effectiveness while reducing dependence on conventional injectable approaches. This track examines innovative oral, transdermal, buccal, nasal, pulmonary, ocular, vaginal, and other mucosal delivery technologies. Sessions will address strategies for overcoming biological barriers such as enzymatic degradation, poor permeability, first-pass metabolism, and limited residence time. Researchers will discuss permeation enhancers, mucoadhesive systems, nanocarriers, microneedles, smart patches, dissolving films, and advanced oral formulations. Particular attention will be given to technologies designed for peptides, proteins, vaccines, and other molecules traditionally administered through injection. The track will also explore patient-centric dosage forms and approaches for improving convenience and adherence. Advances in biomaterials, device engineering, formulation optimization, and controlled-release technologies will be highlighted. Discussions will focus on the translation of promising alternative delivery systems into scalable, safe, stable, and commercially viable pharmaceutical products.

Track 6: Injectable, Implantable & Controlled-Release Systems

Controlled-release technologies are increasingly important for maintaining therapeutic drug concentrations while reducing dosing frequency and improving patient compliance. This track focuses on long-acting injectables, implantable delivery devices, depot formulations, biodegradable systems, and programmable drug-release technologies. Sessions will examine polymer selection, drug encapsulation, degradation mechanisms, release kinetics, device design, and formulation stability. Speakers will discuss applications in chronic diseases, oncology, infectious diseases, hormonal therapies, and neurological conditions. Particular attention will be given to technologies capable of providing sustained or pulsatile drug release over extended periods. Researchers will explore advances in injectable hydrogels, microspheres, implants, in situ forming depots, and responsive delivery systems. Challenges involving injection-site reactions, dose uniformity, manufacturing, sterilization, and regulatory approval will also be considered. The track will bring together formulation scientists, biomedical engineers, clinicians, and industry experts to explore how controlled-release technologies can improve therapeutic consistency and reduce the burden associated with frequent medication administration.

Track 7: Gene, RNA & Nucleic Acid Delivery

The rapid development of genetic medicines has created an urgent need for safe and efficient systems capable of transporting nucleic acids into target cells. This track explores delivery technologies for mRNA, siRNA, miRNA, antisense oligonucleotides, DNA, and other genetic therapeutics. Sessions will examine lipid nanoparticles, polymeric carriers, viral and non-viral vectors, conjugate-based systems, and emerging delivery platforms. Researchers will discuss challenges related to nucleic acid stability, cellular uptake, endosomal escape, tissue targeting, immune responses, and intracellular release. Applications in vaccines, cancer therapy, rare diseases, genetic disorders, and regenerative medicine will be highlighted. Particular emphasis will be placed on improving delivery beyond the liver and developing tissue-specific approaches. The track will also examine manufacturing, scalability, formulation stability, analytical characterization, and regulatory considerations for nucleic-acid-based products. Discussions will showcase how advances in molecular engineering and delivery science are enabling increasingly sophisticated genetic therapies and expanding the therapeutic potential of nucleic acid medicines.

Track 8: Drug Delivery for Cancer & Immunotherapy

Cancer treatment increasingly relies on sophisticated delivery strategies capable of improving therapeutic selectivity and overcoming tumor-associated barriers. This track focuses on drug delivery technologies for chemotherapy, targeted therapeutics, immunotherapy, gene therapy, and combination treatments. Sessions will explore nanoparticles, antibody-drug conjugates, liposomes, tumor-targeting systems, stimuli-responsive carriers, and localized delivery approaches. Speakers will address strategies for improving tumor penetration, intracellular delivery, controlled release, and therapeutic accumulation while minimizing damage to healthy tissues. The track will also examine delivery systems for immune modulators, cancer vaccines, checkpoint inhibitors, and combination therapies. Particular attention will be given to the tumor microenvironment, biological barriers, immune interactions, and mechanisms of therapeutic resistance. Emerging theranostic platforms combining diagnosis, imaging, and treatment will also be discussed. The session provides an interdisciplinary forum for researchers and clinicians to explore how advanced drug delivery can support more precise, effective, and potentially less toxic approaches to cancer management.

Track 9: Brain & CNS Drug Delivery

Delivering therapeutic molecules to the central nervous system remains one of the major challenges in pharmaceutical research because of the protective blood-brain barrier. This track examines innovative strategies for transporting drugs, biologics, genes, and nanoparticles into the brain and spinal cord. Sessions will explore intranasal delivery, receptor-mediated transport, focused ultrasound-assisted delivery, nanoparticles, liposomes, exosomes, and other barrier-modulating technologies. Researchers will discuss approaches for neurological and neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, epilepsy, brain tumors, and multiple sclerosis. Particular attention will be given to improving drug penetration while maintaining safety and minimizing neurotoxicity. The track will also examine advances in imaging-guided delivery, biomarker-based targeting, and personalized CNS therapeutics. Challenges related to formulation, pharmacokinetics, patient variability, and clinical translation will be considered. By bringing together neuroscientists, pharmaceutical researchers, clinicians, and biomedical engineers, this track will explore innovative solutions for overcoming biological barriers and improving treatment options for complex neurological diseases.

Track 10: Biologics, Peptides, Proteins & Vaccine Delivery

Biological medicines offer powerful therapeutic opportunities but present unique delivery challenges because of their structural complexity, instability, limited membrane permeability, and susceptibility to degradation. This track focuses on advanced delivery strategies for peptides, proteins, monoclonal antibodies, enzymes, vaccines, and other biologic therapeutics. Sessions will explore formulation stabilization, encapsulation technologies, controlled release, mucosal delivery, transdermal approaches, and nanoparticle-based systems. Researchers will examine strategies for protecting biologics from enzymatic degradation while maintaining biological activity. Particular attention will be given to next-generation vaccine delivery, including mucosal vaccines, thermostable formulations, and advanced adjuvant systems. Discussions will also address patient-friendly alternatives to conventional injections and technologies designed to improve storage and distribution. Emerging developments in protein engineering, biomaterials, nanotechnology, and formulation science will be highlighted. The track will provide a platform for exploring how innovative delivery technologies can improve the stability, accessibility, scalability, and clinical performance of complex biological medicines.

Track 11: Smart, Stimuli-Responsive & Intelligent Drug Delivery

Smart drug delivery systems are designed to respond to specific biological or environmental signals, enabling controlled therapeutic release at desired locations and times. This track explores systems responsive to pH, temperature, enzymes, light, magnetic fields, ultrasound, redox conditions, and other stimuli. Sessions will examine intelligent nanoparticles, responsive hydrogels, molecularly engineered carriers, programmable delivery systems, and externally triggered platforms. Researchers will discuss how these technologies can improve targeting, reduce systemic exposure, and provide precise control over drug release. Applications in cancer, inflammation, infection, cardiovascular disease, and regenerative medicine will be highlighted. The track will also consider integration with sensors, wearable technologies, artificial intelligence, and digital therapeutics to create adaptive treatment platforms. Challenges involving reproducibility, safety, manufacturing, stability, and clinical translation will be addressed. The session will demonstrate how responsive materials and intelligent engineering principles are creating a new generation of delivery systems capable of adapting to changing physiological environments and supporting more personalized therapeutic interventions.

Track 12: Artificial Intelligence, Machine Learning & Digital Drug Delivery

Artificial intelligence and machine learning are increasingly influencing pharmaceutical formulation, delivery-system design, drug targeting, and clinical decision-making. This track explores how computational technologies can accelerate the discovery and optimization of drug delivery platforms. Sessions will examine AI-assisted formulation development, predictive modeling, pharmacokinetic analysis, drug-release prediction, nanoparticle design, patient stratification, and delivery-route selection. Researchers will discuss how large datasets can be used to identify relationships between formulation parameters and therapeutic outcomes. Digital twins, computational simulations, automated experimentation, and data-driven optimization will also be explored. Particular attention will be given to integrating AI with precision medicine and personalized drug delivery. The track will address challenges involving data quality, model validation, interpretability, regulatory acceptance, and responsible use of artificial intelligence. By connecting pharmaceutical scientists, data scientists, engineers, and clinicians, the sessions will demonstrate how computational approaches can reduce development timelines, improve formulation performance, and support the creation of smarter and more individualized drug delivery systems.

Track 13: Pharmacokinetics, Pharmacodynamics & Bioavailability

Understanding how drug delivery systems influence absorption, distribution, metabolism, and elimination is essential for developing safe and effective therapeutics. This track focuses on pharmacokinetic and pharmacodynamic principles applied to advanced drug delivery. Sessions will explore bioavailability enhancement, drug absorption, tissue distribution, drug release kinetics, clearance, half-life, therapeutic exposure, and dose optimization. Researchers will examine how formulation characteristics influence pharmacological outcomes and how delivery technologies can modify drug disposition. Particular attention will be given to modeling and simulation approaches, population pharmacokinetics, physiologically based pharmacokinetic modeling, and translational strategies. The track will also address bioequivalence, drug-drug interactions, variability between patient populations, and approaches for optimizing therapeutic windows. Discussions will connect formulation development with preclinical and clinical pharmacology to improve prediction of human outcomes. This track provides an important forum for scientists seeking to understand the relationship between delivery-system design, drug exposure, biological response, and clinical efficacy across diverse therapeutic areas.

Track 14: Regulatory Science, Manufacturing & Scale-Up of Drug Delivery Systems

Successful drug delivery technologies require more than scientific innovation; they must also meet stringent quality, manufacturing, safety, and regulatory requirements. This track examines the pathway from laboratory-scale development to commercial pharmaceutical production. Sessions will address regulatory strategies, quality-by-design principles, process development, analytical characterization, validation, stability testing, and scale-up of advanced delivery systems. Particular attention will be given to nanomedicines, complex formulations, combination products, biologics, and controlled-release technologies. Experts will discuss challenges associated with batch consistency, critical quality attributes, manufacturing reproducibility, raw-material control, and long-term stability. The track will also explore regulatory expectations for emerging technologies and strategies for preparing robust development and approval packages. Industry experts and researchers will discuss technology transfer, contract manufacturing, automation, and continuous manufacturing. These sessions will provide practical insights into bridging the gap between promising laboratory discoveries and safe, reproducible, scalable, and regulatory-compliant drug delivery products.

Track 15: Future Directions, Personalized Delivery & Translational Drug Delivery

The future of drug delivery is moving toward increasingly personalized, precise, adaptive, and patient-centered therapeutic systems. This track explores emerging concepts that could redefine pharmaceutical treatment over the coming decade. Sessions will examine personalized drug delivery, theranostics, precision formulations, biomarker-guided targeting, regenerative medicine, wearable delivery technologies, 3D-printed dosage forms, and next-generation implantable systems. Researchers will discuss how patient genetics, physiology, disease characteristics, lifestyle, and treatment response can be incorporated into delivery-system design. Translational challenges from preclinical research to clinical implementation will receive particular attention. The track will also explore collaboration between academia, biotechnology companies, pharmaceutical manufacturers, clinicians, and regulatory organizations. Emerging opportunities created by artificial intelligence, nanotechnology, synthetic biology, and advanced biomaterials will be highlighted. The sessions aim to identify practical pathways for converting innovative concepts into clinically meaningful solutions. Ultimately, this track will examine how future drug delivery technologies can make treatments safer, more effective, accessible, convenient, and increasingly tailored to individual patient needs.

Market Analysis

The global drug delivery market is entering a transformative phase, driven by rapid advances in nanomedicine, targeted therapeutics, biologics, RNA-based medicines, controlled-release technologies, and personalized medicine. Pharmaceutical and biotechnology companies are increasingly investing in delivery platforms that can improve bioavailability, therapeutic precision, patient compliance, and safety while reducing unwanted systemic exposure. Emerging technologies such as lipid nanoparticles, polymeric nanocarriers, smart hydrogels, long-acting injectables, microneedles, implantable systems, and AI-assisted formulation development are creating new opportunities across oncology, vaccines, neurological disorders, metabolic diseases, infectious diseases, and rare diseases. The growing complexity of modern therapeutics is also increasing demand for innovative delivery solutions capable of transporting peptides, proteins, nucleic acids, and other advanced molecules effectively to specific tissues and cells.

The 21st World Drug Delivery Summit 2027 provides a timely platform to explore these rapidly evolving market opportunities and connect scientific innovation with commercial and clinical applications. Key areas shaping the future include AI-driven drug delivery, precision and personalized therapeutics, next-generation nanomedicine, gene and RNA delivery, smart and responsive systems, advanced biologics, and patient-centric delivery technologies. Increasing collaboration between pharmaceutical companies, biotechnology firms, academic institutions, medical-device developers, and regulatory organizations is expected to accelerate the translation of innovative delivery platforms from research laboratories into clinical practice. With these developments reshaping the pharmaceutical landscape, the summit offers an international forum for discussing emerging technologies, investment opportunities, commercialization strategies, regulatory pathways, and the future direction of the global drug-delivery industry.

Past Conference Report

Drug Delivery 2026

The 20th World Drug Delivery Summit, held on June 08–09, 2026, in London, UK, brought together researchers, pharmaceutical scientists, clinicians, academicians, biotechnology professionals, and industry experts to explore emerging developments in drug delivery. The summit was centered on the theme “Redefining Therapeutic Impact through Intelligent Drug Delivery Innovations”, with scientific discussions addressing current challenges and breakthrough approaches in the field. The program highlighted areas including nanotechnology, targeted drug delivery, personalized medicine, advanced biomaterials, biologics, innovative formulation technologies, and emerging drug-delivery platforms. (Drug Delivery Conference)

The summit provided an international platform for knowledge exchange, scientific presentations, networking, and collaboration between academia and industry. Discussions explored emerging technologies designed to improve therapeutic efficacy, safety, bioavailability, patient compliance, and precision in drug administration. Sessions also highlighted AI-driven drug development, advanced nanocarriers, personalized delivery systems, regulatory pathways, clinical translation, and future directions in drug delivery research. The event encouraged researchers and industry professionals to share innovative solutions and identify opportunities for translating laboratory discoveries into practical pharmaceutical applications. Building on the scientific discussions and collaborative spirit of the 20th edition, the 21st World Drug Delivery Summit, scheduled for April 08–09, 2027, in Vienna, Austria, will continue the conversation around next-generation, intelligent, and precision drug-delivery technologies. (Drug Delivery Conference)